Diatretol, an α, α′-dioxo-diketopiperazine, is a potent in vitro and in vivo antimalarial

Abstract

A fungal metabolite, diatretol, has shown to be a promising antimalarial agent. Diatretol displayed potent in vitro antiparasitic activity against the Plasmodium falciparum K1 strain, with an IC₅₀ value of 378 ng ml⁻¹, as well as in vivo efficacy in a Plasmodium berghei-infected mice model, with ca. 50% inhibition at 30 mg/kg (p.o.).

The World Health Organization (WHO) reports that malaria remains endemic in 91 countries, with an estimated 228 million cases and 405,000 deaths in 2018 [1]. The disease shows a global spread in tropical and subtropical regions, with five species of malaria-causing Plasmodium parasites infecting humans. Among them, malaria caused by P. falciparum is the most lethal and is primarily prevalent in sub-Saharan Africa, infection with the other species usually resulting in mild forms of the disease. Antimalarial drugs the main weapon to combat malaria, either for prophylaxis or treatment. WHO now recommends artemisinin-based combination therapies as the preferred treatment option. However, malaria parasites have historically developed resistance to all newly introduced antimalarials extremely quickly, and so drug resistance has remained a continuous problem [2]. Consequently, there has always been a need to find new antimalarial drugs, preferably those that have a unique or different structure or mode of action, to try and offset or delay the emergence of drug resistance. In the course of our screening program on cultured broths of microorganisms, we have discovered various potent antimalarial seed compounds, such as clonocoprogens [3]. A recent screening effort on the “Ōmura Natural Compound (ŌNC) library” allowed us to identify a fungal α,α′-dioxo-diketopiperazine, diatretol (1) [4], as a promising antimalarial agent (Fig. 1). Compound 1 was deposited in the ŌNC library as a result of the chemical investigation of a cultured broth of Metarhizium anisopliae FKI-7223 (Scheme S1). In this paper, we report the in vitro antimalarial activity of 1 as well as lepistamide A (2) [5], lepistamide B (3) [5], megasporizine (4) [6], and albonoursin (5) [7], all of which were derived from 1 (Fig. 1, Schemes S2 and S3). We also detail some structure/activity relationship (SAR) studies. The in vivo efficacy of 1 in a rodent malaria model is also presented.

Fig. 1.

Structures of diatretol (1), lepistamide A (2), lepistamide B (3), megasporizine (4) and albonoursin (5)

Antimalarial activity was assayed as previously reported [8] following approval from the Kitasato Institute Hospital Research Ethics Committee (No 12102), required because of the donation of human erythrocytes from volunteers. In the in vitro evaluation, cultured P. falciparum parasites (multidrug-resistant K1 and drug-sensitive FCR3 strains) were incubated with test compounds (1–5) or clinically used drugs (chloroquine, artemisinin and artesunate) in 96-well culture plates for 72 h. After incubation, parasite lactate dehydrogenase activity was assayed to determine parasite growth and calculate the degree of antimalarial activity. Diatretol (1) displayed potent in vitro antimalarial activity, with IC₅₀ values of 378 and 334 ng ml⁻¹ against K1 and FCR3 strains, respectively (Table 1 and Fig. S2). Lepistamide A (2) showed about 20 times weaker antimalarial activity than 1, with IC₅₀ values of 7884 and 6939 ng ml⁻¹ against K1 and FCR3 strains, respectively. Lepistamide B (3), megasporizine (4) and albonoursin (5) did not show antimalarial activity, even at 12,500 ng ml⁻¹.

Table 1.

In vitro antimalarial activity of 1–5

Compound	IC50 (ng/ml)
	K1 straina	FCR3 strainb
Diatretol (1)	378	334
Lepistamide A (2)	7,884	6,939
Lepistamide B (3)	>12,500	>12,500
Megasporizine (4)	>12,500	>12,500
Albonoursin (5)	>12,500	>12,500
Artemisininc	31	27
Artesunatec	9	7
Chloroquinec	456	40

^aChloroquine-resistant strain

^bChloroquine-sensitive strain

^cDrugs commonly used to treat malaria (IC₅₀: nM)

In vivo antimalarial evaluation of 1 was conducted using the Peters’ 4-day suppressive test [8]. Drug-sensitive rodent malaria P. berghei N strain parasites were used to infect ICR (CD1) mice (Day 0). Administration of 1 or artesunate was done at 30 mg/kg/day by intraperitoneal injection and orally for 4 consecutive days (Day 0–3). Parasitaemia was determined on day 4, with blood smears to calculate the percentage inhibition. As a result (Table 2), 1 showed 54.4% inhibition when used by the intraperitoneal injection at 30 mg/kg/day. More beneficially for the development of antimalarial drugs, 1 displayed 56.2% inhibitory activity by the oral route at the same dose.

Table 2.

In vivo antimalarial activity on Peters’ 4-day suppressive test of 1 and artesunate (30 mg/kg × 4 days) in a mouse model

Compound	Route	Inhibition (%)
Diatretol (1)	i.p.	54.4
	p.o.	56.2
Artesunatea	i.p.	99.1
	p.o.	99.6

^aDrug commonly used to treat malaria

Diatretol (1) [4] belongs to the very rare α,α′-dioxo-diketopiperazine chemical family. The first α,α′-dioxo-diketopiperazine discovered from a naturally occurring source was picroroccellin (Fig. S1) [9]. Other natural compounds with this molecular skeleton are the lepistamides (2, 3) [5], polarazines [10], and pestaloxazine A [11] (all from fungi), the pelopurins [12] (from the marine bacterium Pelomonas puraquae), and bicyclomycin [13] from a Streptomyces organism (Fig. S1). They were reported to possess antibacterial, phytotoxic, cytotoxic, and immunomodulating properties. Diatretol (1) was initially found as a fungal secondary metabolite from a cultured broth of Clitocybe diatrea. It demonstrated little bioactivity, apart from low antibacterial activity [4] and inhibition of the MLC reaction [14]. To the best of our knowledge, this report is the first to detail the in vitro and in vivo antimalarial profile of α,α′-dioxo-diketopiperazines. The antimalarial activity of 1 was about 20-fold greater than that of 2, which is an epimer of 1 at the α-position methoxy function. This result suggested that trans α,α′-dioxo function groups are more important for antimalarial activity than cis α,α′-dioxo function. According to comparative studies of cyclo(L-Val-L-Orn(Z)) and cyclo(L-Val-D-Orn(Z)), the latter showed about 21-fold greater in vitro antimalarial activity against P. berghei [15], which is in agreement with the relationship between 2 and 1. Compound 3, a demethyl analog of 2, displayed no antimalarial activity, indicating that a methoxy functional group at the α-position is also important to bestow antimalarial characteristics. Compounds 4 and 5, dehydrated analogs of 1, similarly showed no antimalarial activity, suggesting the importance of the oxygenated function at the α-position.

Several naturally occurring diketopiperazines have been investigated for potential as antimalarials [16–19]. However, there have been no reports showing clearly both in vitro and in vivo antimalarial activity. We suggest that the α,α′-dioxo-diketopiperazine scaffold might be a key element for development of a novel antimalarial drug. Total synthesis and determination of the absolute configuration of 1 is reported in an accompanying paper [20]. Further studies of 1, including its efficacy against Plasmodium vivax, mode of action, SARs and the creation of a library of more potent derivatives, are urgently required.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary information

The online version of this article (10.1038/s41429-020-00390-2) contains supplementary material, which is available to authorized users.